Compare · CELC vs CI
CELC vs CI
Side-by-side comparison of Celcuity Inc. (CELC) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELC and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $77.03B, about 13.4x CELC ($5.75B).
- Over the past year, CELC is up 965.3% and CI is down 14.0% - CELC leads by 979.3 points.
- CI has been more active in the news (15 items in the past 4 weeks vs 2 for CELC).
- CI has more recent analyst coverage (25 ratings vs 13 for CELC).
- Company
- Celcuity Inc.
- The Cigna Group
- Price
- $118.67-1.17%
- $292.43+2.61%
- Market cap
- $5.75B
- $77.03B
- 1M return
- +9.79%
- +13.35%
- 1Y return
- +965.31%
- -13.99%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 2
- 15
- Recent ratings
- 13
- 25
Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CELC
- Citizens initiated coverage on Celcuity with a new price target
- SEC Form 4 filed by Nigon Richard
- SEC Form DEFA14A filed by Celcuity Inc.
- SEC Form DEF 14A filed by Celcuity Inc.
- SEC Form 4 filed by Buller Richard E
- SEC Form 10-K filed by Celcuity Inc.
- Celcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Amendment: SEC Form SCHEDULE 13D/A filed by Celcuity Inc.
- Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
Latest CI
- The Cigna Group filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Foss Eric J was granted 782 shares, increasing direct ownership by 2% to 36,696 units (SEC Form 4)
- Director Mcclellan Mark B. was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Zarcone Donna F was granted 782 shares, increasing direct ownership by 3% to 27,517 units (SEC Form 4)
- Director Hathi Neesha was granted 782 shares, increasing direct ownership by 23% to 4,151 units (SEC Form 4)
- Director Mazzarella Kathleen M was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Kurian George was granted 782 shares, increasing direct ownership by 21% to 4,560 units (SEC Form 4)
- Director Ross Kimberly A. was granted 782 shares, increasing direct ownership by 17% to 5,294 units (SEC Form 4)
- Director Hennigan Michael J was granted 782 shares, increasing direct ownership by 138% to 1,350 units (SEC Form 4)
- Director Ozuah Philip was granted 782 shares, increasing direct ownership by 43% to 2,583 units (SEC Form 4)